Clinical Trial

Efficacy of the NXSignal Device for the Treatment of Anterior Cruciate Ligament Injuries

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 28, 2025 (before its estimated September 25, 2025 completion). Its status may not reflect the trial's current state.
Summary
Injury to the anterior cruciate ligament (ACL) is very common among sports professionals and the general population \[. Unlike other joint injuries, it is reversible, but it can damage adjacent tissues, particularly the meniscus, and catalyze knee osteoarthritis. ACL injury produces instability, joint mechanical alteration, which can lead to degenerative joint diseases. The goal of treating the injury will be to prevent symptomatic instability, restore normal knee kinematics, and prevent degenerative joint disease . Its usual treatment is surgical and therefore contributes to a significant cost for the health system, both for the surgeries themselves, and for the rehabilitation and subsequent recovery processes. Within recovery therapies, in some cases, and given their popularity within the world of physiotherapy, electrotherapy techniques are proposed, primarily transcutaneous electrical nerve stimulation-type techniques with action on the muscular system and analgesia. An early intervention with neuromuscular electrostimulation electrotherapy (NMES) combined with repeated exercises is effective for the recovery of strength and restoration of the biomechanical symmetry of the limb. There is a diversity of opinions and disparate results regarding the use of this type of technique , in any case, it has been shown that electrical stimulation favors cell migration and joint tissue regeneration.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-01-11; most recent amendment 2025-08-21.
Trial Details
NCT Number NCT05207943
Lead Sponsor University of Las Palmas de Gran Canaria
Conditions Anterior Cruciate Ligament Injuries
Enrollment 40 participants
Start Date 2021-05-25
Primary Completion 2025-09-25 (estimated)
Study Completion 2025-12-25 (estimated)
Updated on ClinicalTrials.gov 2025-08-28